Back to Search
LINDSEY KIRKPATRICK, D.O, PH.D
D.O, PH.D
Pediatric Infectious Diseases Physician
NPI: 1932513447IndividualAccepts Medicare
Specialties, Licenses & Credentials
Pediatric Infectious Diseases PhysicianPrimary
Pediatrics — Pediatric Infectious Diseases
Code: 2080P0208X
02005069A(IN)
Education
KANSAS CITY UNIVERSITY OF MED & BIOSCIENCES, COLLEGE OF OSTEO MED
Class of 2014
Research & Publications (20)
Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL).
PMID 19318355·J Biol Chem·2009
7-preclinical
Pax7 shows higher satellite cell frequencies and concentrations within intrafusal fibers of muscle spindles.
PMID 18541708·J Histochem Cytochem·2008
7-preclinical
The functional domain specificity of self-esteem and the differential prediction of aggression.
PMID 12003475·J Pers Soc Psychol·2002
8-other
Comparative genomic sequence analysis of the FXR gene family: FMR1, FXR1, and FXR2.
PMID 11735223·Genomics·2001
4-observational
Biochemical interactions of the neuronal pentraxins. Neuronal pentraxin (NP) receptor binds to taipoxin and taipoxin-associated calcium-binding protein 49 via NP1 and NP2.
PMID 10748068·J Biol Chem·2000
7-preclinical
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
PMID 19139117·Mol Cancer Ther·2009
7-preclinical
High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes.
PMID 18719666·Obesity (Silver Spring)·2008
4-observational
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.
PMID 16485116·Cancer Chemother Pharmacol·2006
7-preclinical
The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo.
PMID 16257225·Neurobiol Dis·2006
7-preclinical
Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.
PMID 15967100·Neoplasia·2005
7-preclinical
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.
PMID 15559765·Oncol Res·2004
7-preclinical
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.
PMID 15252137·Mol Cancer Ther·2004
7-preclinical
Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.
PMID 15227545·Org Biomol Chem·2004
8-other
Fxr1 knockout mice show a striated muscle phenotype: implications for Fxr1p function in vivo.
PMID 15128702·Hum Mol Genet·2004
7-preclinical
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.
PMID 15026543·Mol Cancer Ther·2004
7-preclinical
Knockout mouse model for Fxr2: a model for mental retardation.
PMID 11875043·Hum Mol Genet·2002
7-preclinical
A comparison of laparoscopic supracervical hysterectomy vs laparoscopically assisted vaginal hysterectomy.
PMID 11344430·Surg Endosc·2001
4-observational
Changes in microtubule stability and density in myelin-deficient shiverer mouse CNS axons.
PMID 11264304·J Neurosci·2001
7-preclinical
The fragile X-related proteins FXR1P and FXR2P contain a functional nucleolar-targeting signal equivalent to the HIV-1 regulatory proteins.
PMID 10888599·Hum Mol Genet·2000
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 705 RILEY HOSPITAL DR
INDIANAPOLIS, IN 46202 - Phone
- (317) 944-7260
Quick Facts
- NPI
- 1932513447
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 12
- Publications
- 20
Are you this provider?
Claim Your Profile